{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:46:48Z","timestamp":1784594808818,"version":"3.55.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Commission, Seventh Framework Programme"},{"DOI":"10.13039\/501100018722","name":"Jaap Schouten Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018722","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Although lipoprotein(a) [Lp(a)] is an established independent risk factor for atherosclerotic cardiovascular disease (ASCVD) in primary prevention settings, it remains unclear whether Lp(a) contributes to an increased risk of adverse cardiovascular events in patients with established ASCVD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The current analysis combines the ATHEROREMO and IBIS-3 observational studies, which together enrolled 798 patients undergoing coronary angiography for stable angina pectoris or acute coronary syndrome. Intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS) were performed to assess coronary plaque characteristics in a nonculprit study segment. Regression models were applied to relate Lp(a) to coronary plaque characteristics and long-term (up to 10 years) clinical outcomes. Lipoprotein(a) was analysed both as a continuous and categorical variable (using 75\u2005nmol\/L and 125\u2005nmol\/L as threshold). Mean age of the patients was 61.6 years (\u00b110.8); 75% were male; 19% had elevated Lp(a) levels (&amp;gt;125\u2005nmol\/L). Patients with Lp(a) &amp;gt; 125\u2005nmol\/L had a significantly higher prevalence of hypercholesterolaemia and prior percutaneous coronary intervention. These patients demonstrated higher IVUS-derived plaque burden [40.7% (\u00b111.5) vs. 38.6% (\u00b110.7), P = 0.028], though no associations were found with other plaque characteristics, e.g. minimum lumen area, lipid core burden index and thin-cap fibroatheroma. No association was found between Lp(a) and \u22125-year major adverse cardiac events (HR 1.06, 95% CI: 0.70\u20131.60, P = 0.78) and 10-year all-cause mortality (HR 0.63, 95% CI: 0.38\u20131.06, P = 0.78).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Among patients with established ASCVD, Lp(a) was associated with plaque burden, supporting evidence that relates Lp(a) to atherosclerotic disease. However, Lp(a) was not associated with long-term mortality or cardiac adverse events in these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwag138","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:32:48Z","timestamp":1773145968000},"source":"Crossref","is-referenced-by-count":4,"title":["Lipoprotein(a), atherosclerotic plaque burden, and long-term cardiovascular outcomes in patients with coronary artery disease"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6736-4073","authenticated-orcid":false,"given":"Jose V F","family":"de Mira","sequence":"first","affiliation":[{"name":"Department of Cardiology, Erasmus MC Cardiovascular Institute, University Medical Center , \u2018s- Gravendijkwal 230, Rotterdam 3015 CE ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina","family":"Vlieger","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Albert Schweitzer Ziekenhuis , Dordrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Mulder","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Erasmus MC Cardiovascular Institute, University Medical Center , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"van der Zee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Erasmus MC Cardiovascular Institute, University Medical Center , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit M","family":"Oemrawsingh","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Amphia Hospital , Breda ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin M","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Albert Schweitzer Ziekenhuis , Dordrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanine Roeters","family":"van Lennep","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Erasmus MC Cardiovascular Institute, University Medical Center , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8628-1410","authenticated-orcid":false,"given":"Joost","family":"Daemen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Erasmus MC Cardiovascular Institute, University Medical Center , \u2018s- Gravendijkwal 230, Rotterdam 3015 CE ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas M","family":"Van Mieghem","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Erasmus MC Cardiovascular Institute, University Medical Center , \u2018s- Gravendijkwal 230, Rotterdam 3015 CE ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2943-5932","authenticated-orcid":false,"given":"Robert-Jan","family":"van Geuns","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Radboud UMC , Nijmegen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick W","family":"Serruys","sequence":"additional","affiliation":[{"name":"CORRIB Research Centre for Advanced Imaging and Core Laboratory, University of Galway , Galway ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2115-9745","authenticated-orcid":false,"given":"Isabella","family":"Kardys","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Erasmus MC Cardiovascular Institute, University Medical Center , \u2018s- Gravendijkwal 230, Rotterdam 3015 CE ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2559-7128","authenticated-orcid":false,"given":"Eric","family":"Boersma","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Erasmus MC Cardiovascular Institute, University Medical Center , \u2018s- Gravendijkwal 230, Rotterdam 3015 CE ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"2026031807265998900_zwag138-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/3491764","article-title":"Lipoprotein(a) the insurgent: a new insight into the structure, function, metabolism, pathogenicity, and medications affecting lipoprotein(a) molecule","volume":"2020","author":"Jawi","year":"2020","journal-title":"J Lipids"},{"key":"2026031807265998900_zwag138-B2","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"2026031807265998900_zwag138-B3","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen city heart study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"key":"2026031807265998900_zwag138-B4","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026031807265998900_zwag138-B5","doi-asserted-by":"crossref","first-page":"zwaf323","DOI":"10.1093\/eurjpc\/zwaf323","article-title":"Evaluating the role of lipoprotein(a) in enhancing risk stratification for the presence and extent of subclinical coronary artery disease burden: a BioHEART-CT study","author":"Fathieh","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"2026031807265998900_zwag138-B6","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J Lipid Res"},{"key":"2026031807265998900_zwag138-B7","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"2026031807265998900_zwag138-B8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.atherosclerosis.2023.04.012","article-title":"Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European atherosclerosis society","volume":"374","author":"Kronenberg","year":"2023","journal-title":"Atherosclerosis"},{"key":"2026031807265998900_zwag138-B9","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jacc.2013.06.051","article-title":"Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (atherothrombosis intervention in metabolic syndrome with low HDL\/high triglyceride and impact on global health outcomes)","volume":"62","author":"Albers","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026031807265998900_zwag138-B10","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"key":"2026031807265998900_zwag138-B11","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jacc.2013.09.042","article-title":"Lipoprotein(a) for risk assessment in patients with established coronary artery disease","volume":"63","author":"O'Donoghue","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026031807265998900_zwag138-B12","doi-asserted-by":"crossref","first-page":"953","DOI":"10.4244\/EIJY13M08_01","article-title":"Relation of genetic profile and novel circulating biomarkers with coronary plaque phenotype as determined by intravascular ultrasound: rationale and design of the ATHEROREMO-IVUS study","volume":"10","author":"de Boer","year":"2014","journal-title":"EuroIntervention"},{"key":"2026031807265998900_zwag138-B13","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/eurheartj\/eht484","article-title":"In vivo detection of high-risk coronary plaques by radiofrequency intravascular ultrasound and cardiovascular outcome: results of the ATHEROREMO-IVUS study","volume":"35","author":"Cheng","year":"2014","journal-title":"Eur Heart J"},{"key":"2026031807265998900_zwag138-B14","first-page":"113","article-title":"Automated coronary plaque characterisation with intravascular ultrasound backscatter: ex vivo validation","volume":"3","author":"Nair","year":"2007","journal-title":"EuroIntervention"},{"key":"2026031807265998900_zwag138-B15","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.jacc.2005.07.064","article-title":"In vivo intravascular ultrasound-derived thin-cap fibroatheroma detection using ultrasound radiofrequency data analysis","volume":"46","author":"Rodriguez-Granillo","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2026031807265998900_zwag138-B16","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"2026031807265998900_zwag138-B17","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)","volume":"33","author":"Members","year":"2012","journal-title":"Eur Heart J"},{"key":"2026031807265998900_zwag138-B18","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"2026031807265998900_zwag138-B19","doi-asserted-by":"crossref","first-page":"e018023","DOI":"10.1161\/JAHA.120.018023","article-title":"Association of Serum lipoprotein (a) levels and coronary atheroma volume by intravascular ultrasound","volume":"9","author":"Huded","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026031807265998900_zwag138-B20","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1001\/jamacardio.2024.1874","article-title":"Lipoprotein(a) and long-term plaque progression, low-density plaque, and pericoronary inflammation","volume":"9","author":"Nurmohamed","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2026031807265998900_zwag138-B21","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.jacc.2025.04.013","article-title":"Lipoprotein(a), cholesterol, triglyceride levels, and vulnerable coronary plaques: a PROSPECT II substudy","volume":"85","author":"Erlinge","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026031807265998900_zwag138-B22","first-page":"101120","article-title":"Lipoprotein (a) levels and vulnerable characteristics in nonculprit plaque in patients with acute coronary syndrome","volume":"43","author":"Kato","year":"2022","journal-title":"Int J Cardiol Heart Vasc"},{"key":"2026031807265998900_zwag138-B23","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.atherosclerosis.2016.01.020","article-title":"Lipoprotein (a) is related to coronary atherosclerotic burden and a vulnerable plaque phenotype in angiographically obstructive coronary artery disease","volume":"246","author":"Niccoli","year":"2016","journal-title":"Atherosclerosis"},{"key":"2026031807265998900_zwag138-B24","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jcmg.2014.10.015","article-title":"Accuracy of OCT, grayscale IVUS, and their combination for the diagnosis of coronary TCFA: an ex vivo validation study","volume":"8","author":"Fujii","year":"2015","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026031807265998900_zwag138-B25","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/ehjci\/jeab034","article-title":"Clinical impact of PCSK9 inhibitor on stabilization and regression of lipid-rich coronary plaques: a near-infrared spectroscopy study","volume":"23","author":"Ota","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026031807265998900_zwag138-B26","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4244\/EIJ-D-21-00701","article-title":"Lipid-rich plaque density and low-density lipoprotein cholesterol in statin-treated versus statin-na\u00efve patients: a post hoc analysis of the LRP study","volume":"18","author":"Torguson","year":"2022","journal-title":"EuroIntervention"},{"key":"2026031807265998900_zwag138-B27","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jacc.2021.10.044","article-title":"Association of lipoprotein(a) with atherosclerotic plaque progression","volume":"79","author":"Kaiser","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026031807265998900_zwag138-B28","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S2213-8587(17)30096-7","article-title":"Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study","volume":"5","author":"Zewinger","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026031807265998900_zwag138-B29","doi-asserted-by":"crossref","first-page":"100053","DOI":"10.1016\/j.jlr.2021.100053","article-title":"Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements","volume":"62","author":"Yeang","year":"2021","journal-title":"J Lipid Res"},{"key":"2026031807265998900_zwag138-B30","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/eurjpc\/zwae032","article-title":"Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research","volume":"31","author":"Kamstrup","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2026031807265998900_zwag138-B31","doi-asserted-by":"crossref","first-page":"120447","DOI":"10.1016\/j.atherosclerosis.2025.120447","article-title":"Lp(a) testing for the primary prevention of cardiovascular disease in high-income countries: a cost-effectiveness analysis","volume":"409","author":"Morton","year":"2025","journal-title":"Atherosclerosis"},{"key":"2026031807265998900_zwag138-B32","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European atherosclerosis society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"key":"2026031807265998900_zwag138-B33","doi-asserted-by":"crossref","first-page":"zwaf649","DOI":"10.1093\/eurjpc\/zwaf649","article-title":"Clinical significance of elevated lipoprotein(a) in primary and secondary prevention: a multi-institutional study","author":"Chen","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"2026031807265998900_zwag138-B34","doi-asserted-by":"crossref","first-page":"100366","DOI":"10.1016\/j.ajpc.2022.100366","article-title":"Intensive lipid lowering agents and coronary atherosclerosis: insights from intravascular imaging","volume":"11","author":"Giovanni","year":"2022","journal-title":"Am J Prev Cardiol"},{"key":"2026031807265998900_zwag138-B35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/ehjci\/jeu169","article-title":"The relationship among extent of lipid-rich plaque, lesion characteristics, and plaque progression\/regression in patients with coronary artery disease: a serial near-infrared spectroscopy and intravascular ultrasound study","volume":"16","author":"Dohi","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026031807265998900_zwag138-B36","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis","volume":"327","author":"R\u00e4ber","year":"2022","journal-title":"JAMA"},{"key":"2026031807265998900_zwag138-B37","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1177\/2047487320937489","article-title":"Not only the status of body weight and metabolic health matters for cardiovascular events, but also the temporal changes","volume":"28","author":"Christou","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2026031807265998900_zwag138-B38","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3390\/ph16050750","article-title":"Effects of lipid-modifying and other drugs on lipoprotein(a) levels-potent clinical implications","volume":"16","author":"Koutsogianni","year":"2023","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"key":"2026031807265998900_zwag138-B39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","article-title":"Design and rationale of lp(a)HORIZON trial: assessing the effect of lipoprotein(a) lowering with pelacarsen on Major cardiovascular events in patients with CVD and elevated lp(a)","volume":"287","author":"Cho","year":"2025","journal-title":"Am Heart J"},{"key":"2026031807265998900_zwag138-B40","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.atherosclerosis.2022.06.1023","article-title":"Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: the Copenhagen general population study","volume":"355","author":"Simony","year":"2022","journal-title":"Atherosclerosis"},{"key":"2026031807265998900_zwag138-B41","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"404","author":"Nordestgaard","year":"2024","journal-title":"Lancet (London, England)"},{"key":"2026031807265998900_zwag138-B42","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.jacc.2025.04.010","article-title":"Global variation in lipoprotein(a) levels among patients with coronary heart disease: insights from the INTERASPIRE study and implications for emerging lp(a)-lowering therapies","volume":"85","author":"Barkas","year":"2025","journal-title":"J Am Coll Cardiol"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag138\/67316598\/zwag138.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag138\/67316598\/zwag138.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:27:14Z","timestamp":1773833234000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article\/doi\/10.1093\/eurjpc\/zwag138\/8516387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":42,"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwag138","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"article-number":"zwag138"}}